| Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. | |
| | |
MedLine Citation:
|
PMID: 20337816 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Psoriasis is a chronic, systemic inflammatory disorder manifesting primarily in skin and potentially in joints, frequently necessitating treatment with conventional systemic therapies, phototherapy or biological agents. Patients with moderate to severe disease suffer a diminished quality of life, experience significant comorbidities and have a higher mortality. Although traditional treatments are effective in the short-term, their use is often limited by concerns over long-term toxicity, including end-organ damage and risk of malignancy. Combination therapy is a commonly used approach and is often more effective than any single agent. Lower doses of two treatments in combination can also minimize potential side effects from a single agent at higher doses. Etanercept is a recombinant human tumour necrosis factor (TNF)α receptor (p75) protein fused with the Fc portion of IgG1 that binds to TNFα. This article reviews the evidence on the efficacy and safety of etanercept in combination with methotrexate, acitretin, narrowband UVB and cyclosporin. The largest body of evidence assesses the combination with methotrexate, although evidence is available for the other combinations. Data suggest that although highly effective as monotherapy, etanercept in combination with a conventional systemic agent can enhance efficacy and allow drug sparing. Potentially, the combination may also result in faster treatment responses and permit safe transitioning from one systemic agent to another. Evidence to date suggests that these benefits can be achieved without significant additional toxicity, although long-term data on the efficacy and safety of the combination in psoriatic populations is limited and further evaluation is warranted. |
| | |
Authors:
|
P A Foley; C Quirk; J R Sullivan; C Dolianitis; S P Hack; K Thirunavukkarasu; A J Cooper |
Related Documents
:
|
2076716 - Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema... 17309456 - Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic... 12399676 - Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-mo... 17374316 - Efalizumab for the treatment of psoriatic arthritis. 2375906 - Impressions of parkinsonian patients from their recorded voices. 8257196 - Comparison of effectiveness of group interventions for depression in women. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of the European Academy of Dermatology and Venereology : JEADV Volume: 24 ISSN: 1468-3083 ISO Abbreviation: J Eur Acad Dermatol Venereol Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-11-05 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9216037 Medline TA: J Eur Acad Dermatol Venereol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1135-43 Citation Subset: IM |
Copyright Information:
|
© 2010 The Authors. Journal of the European Academy of Dermatology and Venereology © 2010 European Academy of Dermatology and Venereology. |
Affiliation:
|
Skin and Cancer Foundation, Carlton, Vic, Australia. pfoley@skincancer.asn.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment ...
Next Document: Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass i...